Osada M, Ishioka C, Murakawa Y, Ichinohasama R, Kanamaru R, Ikawa S
Dept. of Clinical Oncology, Tohoku University.
Gan To Kagaku Ryoho. 1997 Feb;24(4):471-5.
We studied the clinical significance of the extent of p53 protein expression by immunohistochemical analysis and p53 mutations by functional analysis of p53 in 42 patients with high and intermediate grade of Non-Hodgkin's Lymphoma (NHL). Neither p53 expression nor mutation correlated with short survival or resistance to chemoradiotherapy, implying that p53 mutation is not a prognostic factor in NHL.
我们通过免疫组织化学分析研究了42例高中度非霍奇金淋巴瘤（NHL）患者中p53蛋白表达程度的临床意义，并通过p53功能分析研究了p53突变情况。p53表达和突变均与生存期短或放化疗耐药无关，这表明p53突变不是NHL的预后因素。
